India is witnessing an outbreak of MUCORMYCOSIS – a very fast spreading fungal infection especially for post COVID infection and recovery because of low immune system in the patients. The most recommended treatment for this infection is Amphotericin B injection.
As per company statement, Synbiotics Limited, a subsidiary of ASE is the only manufacturer of the Active Pharmaceutical Ingredient (API) Amphotericin B in India.
Looking at the current outbreak of MUCORMYCOSIS and expected requirement, Synbiotics has ramped up the manufacturing capacity to meet the requirement of this most effective anti-fungal Antibiotic in the post Covid crisis.
Synbiotics Limited has the State of the Art fermentation plant for the manufacturing of the API Amphotericin B.